Insulet 

€206.3
61
+€2.1+1.03% Wednesday 19:55

統計

當日最高
206.3
當日最低
199.6
52週最高
-
52週最低
-
成交量
0
平均成交量
-
市值
14.22B
市盈率
36.67
股息收益率
-
股息
-

即將到來

收益

31Oct預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
0.1
0.86
1.61
2.37
預期每股收益
0.71183851684
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 GOV.F 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

229.38平均價格目標
最高估價為 €260。
來自過去 6 個月內的 9 個評級。這不是投資建議。
買入
67%
持有
33%
賣出
0%

關於

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Show more...
首席執行官
Dr. James R. Hollingshead Ph.D.
員工
3000
國家
US
ISIN
US45784P1012
WKN
000A0MQX8

上市公司